

Supplementary file 3: Impact of study characteristics on SF-36 scores: Sensitivity and Subgroup Analyses.

	PF	RP	BP	GH	PCS	VT	SF	RE	MH	MCS
Primary Analysis	61.44(56.36-66.52)	47.43(42.33-52.53)	56.67 (52.00-61.34)	45.46 (44.20-48.72)	46.10 (43.09-49.10)	51.41 (48.00-54.81)	62.12 (57.39-66.86)	55.94 (49.98-61.90)	59.16 (55.45-62.86)	50.37 (47.78-52.87)
	I ² = 99.0%	I ² = 98.4%	I ² = 98.6%	I ² = 95.7%	I ² = 98.8%	I ² = 98.0%	I ² = 98.6%	I ² = 98.5%	I ² = 98.5%	I ² = 98.0%
	29 studies	29 studies	29 studies	29 studies	28 studies	29 studies	29 studies	29 studies	29 studies	28 studies
	5398 patients	5398 patients	5398 patients	5398 patients	5839 patients	5398 patients	5398 patients	5398 patients	5398 patients	5839 patients
Sensitivity Analysis										
Excluding studies with unreported PR or PR<75%	61.30(51.73-70.87)	48.53(42.42-54.65)	58.89(48.70 -69.07)	44.16(41.31-47.01)	48.60(42.89-54.30)	52.36(47.74- 56.97)	61.89(52.42-71.35)	53.05(46.97- 59.12)	58.23(51.85-64.60)	51.40(45.08-57.71)
	I ² = 99.4%	I ² = 97.7%	I ² = 99.3%	I ² =92.7 %	I ² =98.6 %	I ² = 97.3%	I ² = 99.1%	I ² = 96.5%	I ² = 98.5%	I ² =98.8 %
	11 studies	11 studies	11 studies	11 studies	11 studies	11 studies	11 studies	11 studies	11 studies	11 studies
	1668 patients	1668 patients	1668 patients	1668 patients	1671 patients	1668 patients	1668 patients	1668 patients	1668 patients	1671 patients
Excluding non-randomized, convenience or unreported sampling method	64.07(55.90-72.23)	52.26(45.82-58.70)	58.70(50.17-67.21)	45.45(42.37-48.53)	50.91(44.18-57.64)	51.02(45.40-56.63)	63.08(55.61-70.56)	58.22(51.88-64.56)	59.74(53.29-66.19)	52.93(47.26-58.59)
	I ² = 99.3%	I ² = 98.1%	I ² = 99.2 %	I ² =94.9 %	I ² =99.3 %	I ² = 98.5%	I ² = 98.9 %	I ² = 97.0%	I ² = 98.8%	I ² = 98.9 %
	13 studies	13 studies	13 studies	13 studies	12 studies	13 studies	13 studies	13 studies	13 studies	12 studies
	3053 patients	3053 patients	3053 patients	3053 patients	2968 patients	3053 patients	3053 patients	3053 patients	3053 patients	2968 patients
Excluding studies with sample size <150	66.10(57.37-74.82)	47.98(40.76 -55.20)	62.82(52.55- 73.10)	45.24(41.32-49.15)	46.96(42.43-51.50)	49.32(42.62-56.02)	65.87(57.48-74.26)	58.05(51.22 -64.88)	60.33(53.70 -66.96)	51.39(47.60-55.18)
	I ² = 99.3%	I ² = 98.2 %	I ² =99.4 %	I ² = 96.9 %	I ² = 99.2%	I ² = 99.0 %	I ² = 99.1 %	I ² = 96.9 %	I ² = 99.0 %	I ² = 98.7 %
	8 studies	8 studies	8 studies	8 studies	12 studies	8 studies	8 studies	8 studies	8 studies	12 studies
	3302 patients	3302 patients	3302 patients	3302 patients	4260 patients	3302 patients	3302 patients	3302 patients	3302 patients	4260 patients
Excluding studies with unreported eligibility criteria for patients	61.58(56.16-67.00)	47.41(41.98-52.83)	56.80(51.78-61.82)	46.63(44.21 -49.04)	47.40(44.18-50.62)	51.67(48.05-55.29)	61.67(56.64-66.70)	55.50(49.29-61.69)	58.41(54.48-62.35)	51.00(48.24-53.78)
	I ² = 99.1 %	I ² = 98.5 %	I ² = 98.8%	I ² = 96.1 %	I ² = 98.9%	I ² = 98.2%	I ² = 98.7%	I ² = 98.6%	I ² = 98.6%	I ² = 98.2 %
	26 studies	26 studies	26 studies	26 studies	25 studies	26 studies	26 studies	26 studies	26 studies	25 studies
	5153 patients	5153 patients	5153 patients	5153 patients	5564 patients	5153 patients	5153 patients	5153 patients	5153 patients	5564 patients

Excluding studies		63.27(57.13-69.41)	48.20(41.24-55.15)	57.49(52.29-62.68)	46.35(43.97-48.73)	48.07(44.44-51.70)	52.20(49.63-54.76)	63.20(57.55-68.84)	56.24(48.06-64.41)	59.01(54.43-63.59)	51.07(47.65-54.49)
using subsets of patients		I ² = 98.6 %	I ² = 98.1 %	I ² = 97.8%	I ² = 92.2%	I ² = 98.2%	I ² = 93.0 %	I ² =98.2%	I ² = 98.7%	I ² = 98.0 %	I ² = 97.7%
		22 studies	22 studies	22 studies	22 studies	20 studies	22 studies	22 studies	22 studies	22 studies	20 studies
		2802 patients	2802 patients	2802 patients	2802 patients	2858 patients	2802 patients	2802 patients	2802 patients	2802 patients	2858 patients
Subgroup analysis											
Study design	Cross-	59.29(52.38-66.20)	46.02(38.52-53.52)	55.92(49.29-62.56)	46.13 (43.31-48.95)	44.13(40.20-48.07)	52.55 (48.67-56.43)	60.70 (53.97-67.42)	53.18 (44.69-61.68)	58.52 (54.35-62.69)	49.01(45.14-52.87)
	Sectional	I ² = 99.1 %	I ² = 98.9 %	I ² = 98.8%	I ² = 95.2%	I ² = 98.4 %	I ² =97.4%	I ² = 98.9 %	I ² = 98.9 %	I ² =98.0%	I ² = 98.0%
		18 studies	18 studies	18 studies	18studies	16 studies	18 studies	18 studies	18 studies	18 studies	16 studies
		2556 patients	2556 patients	2556 patients	2556 patients	2448 patients	2556 patients	2556 patients	2556patients	2556 patients	2448 patients
	Case-	71.15(60.95-81.36)	52.11(36.50-67.72)	63.66(50.80-76.52)	46.97(43.02-50.91)	60.43(48.10-72.75)	52.74(46.39-59.09)	67.87(62.51-73.22)	67.34 (61.54-73.15)	58.65 (48.09-69.22)	61.69(51.83-71.56)
	Control	I ² = 96.8 %	I ² =95.6 %	I ² = 97.2%	I ² = 83.1 %	I ² = 98.3 %	I ² = 93.1%	I ² = 85.8%	I ² = 70.7 %	I ² =97.7%	I ² = 97.6%
		5 studies	5 studies	5 studies	5 studies	5 studies	5 studies	5 studies	5 studies	5 studies	5 studies
		591 patients	591 patients	591 patients	591 patients	586 patients	591 patients	591 patients	591 patients	591 patients	586 patients
	Longitu-	59.86(52.34-67.37)	46.91(41.42-52.40)	52.90(48.82-56.99)	47.05(41.98-52.12)	40.73(37.08-44.38)	46.83(41.26-52.39)	61.91(52.84-70.98)	55.28 (47.97-62.60)	61.44 (51.46-71.42)	45.56(44.10-47.02)
	dinal	I ² = 98.1 %	I ² = 92.7 %	I ² = 93.7%	I ² = 97.0%	I ² = 98.3%	I ² = 97.4 %	I ² = 98.6%	I ² = 95.6%	I ² =99.3%	I ² = 87.9 %
		6 studies	6 studies	6 studies	6 studies	7 studies	6 studies	6 studies	6 studies	6 studies	7 studies
		2251 patients	2251 patients	2251 patients	2251 patients	2805 patients	2251 patients	2251 patients	2251 patients	2251 patients	2805 patients
Publication decades	1990s	67.79(59.82-75.77)	56.79(49.99-63.60)	59.12(38.83-79.40)	56.02(51.79-60.26)	40.80(39.27-42.33)	52.47(42.20-62.76)	69.87(63.47-76.27)	68.70(63.03-74.36)	67.51(65.09-69.93)	45.90(44.31-47.49)
		I ² = 99.3 %	I ² = 16.9 %	I ² = 97.2 %	I ² = 40.8 %	I ² = 0.0 %	I ² = 91.0 %	I ² = 66.6 %	I ² = 0.0 %	I ² = 0.0 %	I ² =0.0 %
		2 studies	2 studies	2 studies	2 studies	1 studies	2 studies	2 studies	2 studies	2 studies	1 studies
		169 patients	169 patients	169 patients	169 patients	220 patients	169 patients	169 patients	169 patients	169 patients	220 patients
	2000s	66.82(58.25-75.38)	48.90(36.80-60.99)	59.73(52.26-67.21)	48.03(44.75-51.31)	46.70(41.97-51.42)	52.09(49.08-55.10)	65.99(58.21-73.77)	56.20(41.65-70.76)	61.51(55.26-67.76)	49.72(45.75-53.70)
		I ² = 98.6 %	I ² = 98.7%	I ² =97.8 %	I ² =91.2 %	I ² = 98.6 %	I ² = 89.3 %	I ² = 98.2 %	I ² = 99.1 %	I ² = 97.8 %	I ² = 97.6 %
		12 studies	12 studies	12 studies	12 studies	13 studies	12 studies	12 studies	12 studies	12 studies	13 studies
		1564 patients	1564 patients	1564 patients	1564 patients	2097 patients	1564 patients	1564 patients	1564 patients	1564 patients	2097 patients
	2010s	56.42(49.21-63.63)	45.36(39.91-50.79)	53.95(47.32-60.59)	44.04(40.89-47.18)	45.96(41.43-50.50)	50.79(45.35-56.23)	58.11(51.25-64.97)	54.13(48.94-59.31)	56.20(51.00-61.38)	51.33(47.57-55.10)

		1811 patients	1811 patients	1811 patients	1811 patients	1811 patients	1811 patients	1811 patients	1811 patients	1811 patients	1811 patients
Economic level	develop-	64.10(55.78-72.43)	50.26 (43.54-56.99)	60.01(50.57-69.44)	46.53 (43.58-49.49)	50.48(44.49-56.46)	54.60(50.44-58.75)	63.49(54.70-72.28)	55.71(48.75-62.67)	56.07(50.01-62.12)	52.21(45.86-58.56)
	ing	I ² =99.2%	I ² =97.5%	I ² =99.1%	I ² =92.5%	I ² = 98.7%	I ² =96.4%	I ² =99.1%	I ² =96.5%	I ² =98.1%	I ² = 98.7%
		12 studies	12 studies	12 studies	12 studies	10 studies	12 studies	12 studies	12 studies	12 studies	10 studies
		1743 patients	1743 patients	1743 patients	1743 patients	1616 patients	1743 patients	1743 patients	1743 patients	1743 patients	1616 patients
	develop-	59.55(53.08-66.02)	45.45 (38.75-52.16)	54.23(50.21-58.25)	46.37(43.08-49.66)	43.59(40.56 -46.61)	49.10 (44.24-53.97)	61.14 (55.56-66.73)	56.11(47.18-65.03)	61.33(56.61-66.05)	49.25(46.86-51.64)
	ed	I ² = 98.7%	I ² = 98.2%	I ² = 96.6%	I ² =96.8%	I ² = 98.4%	I ² = 98.4%	I ² =98.1%	I ² = 98.9%	I ² = 98.7%	I ² = 97.0%
		17studies	17studies	17studies	17studies	18 studies	17studies	17studies	17studies	17studies	18 studies
		3655 patients	3655 patients	3655 patients	3655 patients	2449 patients	3655 patients	3655 patients	3655 patients	3655 patients	2449 patients